Also announced - new head-to-head trials, LUX-Lung 7 and LUX-Lung 8, initiated to further evaluate afatinib in non-small cell lung cancer (NSCLC)

FOR NON-US MEDIA ONLY

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. LUX-Lung 3, which compares afatinib to standard platinum based"......

For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.